muscular disease: Acquired, familial, and congenital disorders of skeletal muscle and smooth muscle.
Muscle wasting and atrophy, not elsewhere classified
DOID EFO Endpoint Browser PheWeb
M13_MUSCLEATROPH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
247 |
4. Check minimum number of eventsNone |
247 |
5. Include endpointsNone |
247 |
6. Filter based on genotype QC (FinnGen only) |
224 |
Control definitions (FinnGen only)
- Control exclude
- M13_SOFTTISSUE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M62
- Name in latin
- Atrophia et degeneratio musculi non alibi classificatae
Similar endpoints
↥List of similar endpoints to
Muscle wasting and atrophy, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Disorders of muscles
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1539 | 650 | 867 |
| Only index persons | 1277 | 562 | 715 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 58.20 | 59.33 | 57.32 |
| Only index persons | 57.86 | 58.68 | 57.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 224 | 104 | 120 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 58.33 | 55.07 | 61.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 230
- Matched controls
- 2300
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
+∞
251.8
193
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
10.6
25.9
30
32
G72.9
ICD-10 Finland
Myopathy, unspecified
72.8
23.4
26
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.3
22.3
42
79
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.8
21.8
29
37
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.7
20.3
55
143
73310
ICD-8 Finland
Other diseases of muscle, tendon and fascia, Muscular atrophy (idiopathic)
+∞
20.1
19
*
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
6.7
15.0
25
41
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
6.2
15.0
27
48
M79.6
ICD-10 Finland
Pain in limb
3.0
14.6
100
469
7282A
ICD-9 Finland
Disorders of muscle, ligament and fascia, Muscular wasting and disuse atrophy, not elsewhere classified
+∞
13.7
13
*
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
5.4
13.0
27
55
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.7
12.1
30
71
N03AX12
ATC
[U] gabapentin; oral
3.6
12.0
46
151
N02AX02
ATC
tramadol; systemic, rectal
2.6
11.5
109
589
M54.5
ICD-10 Finland
Low back pain
2.6
10.6
85
420
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
17.1
10.5
16
10
M48.0
ICD-10 Finland
Spinal stenosis
3.5
10.3
39
126
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.6
10.3
37
116
M13.9
ICD-10 Finland
Arthritis, unspecified
4.4
10.1
27
68
M54.1
ICD-10 Finland
Radiculopathy
8.1
9.7
21
28
A28
ICPC
Limited function/disability NOS
2.7
9.5
65
295
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
9.4
9
*
L28
ICPC
Limited function/disability (L)
2.7
9.4
61
269
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
9.1
60
267
ACC59
NOMESCO Finland
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
9.1
8.5
17
20
G56.0
ICD-10 Finland
Carpal tunnel syndrome
3.4
8.4
33
109
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
8.4
8
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
8.4
8
*
TAB00
NOMESCO Finland
Lumbar puncture
6.7
8.2
20
32
G56.2
ICD-10 Finland
Lesion of ulnar nerve
9.5
8.2
16
18
N06AX21
ATC
duloxetine; oral
3.7
7.9
26
76
M25.5
ICD-10 Finland
Pain in joint
2.4
7.7
71
366
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
7.7
48
206
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
14.0
7.5
12
9
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
8.8
7.4
15
18
M60.9
ICD-10 Finland
Myositis, unspecified
+∞
7.3
7
*
T84.0
ICD-10 Finland
Mechanical complication of internal joint prosthesis
7.7
7.3
16
22
SPAT1229
SPAT
Assessment of need for aid
3.4
7.3
27
86
M17.1
ICD-10 Finland
Other primary gonarthrosis
2.4
7.2
57
274
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.8
7.1
22
62
Z3226
NOMESCO Finland
Physiotherapist
2.6
6.9
47
210
N03AX16
ATC
[U] pregabalin
2.4
6.9
57
279
G12.2
ICD-10 Finland
Motor neuron disease
17.3
6.8
10
6
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
6.2
6.8
17
29
M47.80
ICD-10 Finland
Other spondylosis, multiple sites in spine
8.2
6.7
14
18
N02BF01
ATC
gabapentin; oral
3.5
6.6
24
75
M05BA04
ATC
alendronic acid; oral
3.0
6.6
30
108
M19.0
ICD-10 Finland
Primary arthrosis of other joints
3.4
6.5
24
76
TQW40
NOMESCO Finland
Remowal of suture of skin
3.5
6.5
23
71
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
71.8
6.5
7
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.3
6.4
25
82
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
6.4
70
385
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
6.4
75
424
ACC53
NOMESCO Finland
Release of ulnar nerve
18.6
6.3
9
5
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
+∞
6.3
6
*
M60.8
ICD-10 Finland
Other myositis
+∞
6.3
6
*
M20.1
ICD-10 Finland
Hallux valgus (acquired)
3.3
6.2
24
78
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
4.3
6.2
16
39
M16.9
ICD-10 Finland
Coxarthrosis, unspecified
3.6
6.0
20
59
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
144
966
2.31
8.53
8.3
7.7
1.21
1.21
mmol/l
0.19
132
831
133
883
2.20
7.83
7.6
7.1
1.21
1.21
mmol/l
0.01
128
811
132
879
2.18
7.64
4.8
4.8
34.98
35.31
g/l
0.24
122
835
17
41
4.40
6.67
1.8
1.3
—
—
—
0
0
62
330
2.20
6.11
2.7
3.9
0.83
0.81
mmol/l
0.54
55
315
170
1335
2.05
5.38
5.6
3.8
11.91
12.38
mm/h
0.19
159
1227
8
9
9.16
4.31
1.0
1.0
—
—
—
0
0
9
13
7.15
4.20
1.0
1.1
—
—
—
0
0
9
14
6.64
4.02
1.0
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
50
3.14
3.76
3.2
3.0
0.28
0.34
iu/ml
—
9
27
108
792
1.69
3.68
2.7
2.3
78.72
75.18
nmol/l
0.62
101
704
31
154
2.17
3.56
1.9
1.6
—
—
—
0
0
6
6
10.22
3.51
1.2
1.0
—
—
—
0
0
56
347
1.81
3.44
1.9
1.7
909.62
1154.95
nmol/l
1.62
46
257
134
1056
1.64
3.35
9.3
9.8
4.42
4.26
e9/l
0.33
123
928
68
452
1.72
3.27
2.8
3.0
334.82
354.52
umol/l
0.90
61
384
12
34
3.67
3.25
1.6
1.4
—
—
—
0
0
113
862
1.61
3.16
2.6
2.9
—
—
estimate
—
0
0
111
844
1.61
3.14
2.5
2.1
100.57
92.32
pmol/l
0.76
69
445
41
240
1.86
3.00
1.4
1.2
2.82
17.05
u/ml
1.48
12
88
43
258
1.82
2.91
9.6
9.4
1.71
0.83
mmol/l
0.80
34
217
21
97
2.28
2.87
1.4
1.3
—
—
—
0
0
13
47
2.87
2.87
1.2
1.4
—
—
—
0
0
44
268
1.79
2.84
1.4
1.2
14.30
34.07
iu/ml
1.63
14
80
7
14
5.12
2.75
5.0
2.1
13.77
13.12
%
—
7
14
97
733
1.56
2.71
5.9
4.1
63.07
38.77
ng/l
0.74
73
568
6
10
6.13
2.71
1.0
1.0
—
—
—
0
0
85
630
1.55
2.56
4.0
3.5
1747.36
1508.85
ng/l
0.27
76
548
55
367
1.66
2.56
1.5
1.2
0.52
1.40
u/ml
1.43
15
100
89
676
1.52
2.36
3.2
3.7
2.34
2.35
mmol/l
0.38
80
617
68
499
1.51
2.09
3.0
2.1
3.02
3.05
mg/l
0.04
59
425
74
553
1.50
2.09
1.7
1.7
22.76
20.01
nmol/l
0.66
65
457
5
10
5.08
2.08
1.2
3.4
395.00
1255.80
u/ml
—
5
10
56
403
1.51
1.87
1.9
1.6
1.17
1.68
mg/l
1.01
48
319
118
980
1.42
1.87
5.6
3.8
0.00
0.00
estimate
-0.00
19
202
5
12
4.23
1.83
2.6
1.8
—
—
—
0
0
164
1451
1.45
1.79
9.3
8.1
79.68
82.11
u/l
0.33
159
1374
26
157
1.74
1.75
2.8
2.8
57.40
62.02
ml/min/173m2
—
10
65
137
1177
1.41
1.74
6.7
5.4
6.89
6.78
mmol/l
0.21
132
1126
58
429
1.47
1.69
6.2
4.0
1.02
1.02
kg/l
0.37
51
286
5
14
3.63
1.62
1.2
1.2
—
—
—
0
0
56
418
1.45
1.56
2.6
3.0
2.45
2.46
mmol/l
0.26
50
378
8
33
2.47
1.55
4.1
5.6
369.88
363.56
umol/l
—
8
27
196
1816
1.54
1.51
24.3
16.0
25.40
26.39
mg/l
0.17
173
1499
55
412
1.44
1.50
1.6
1.8
88372507.42
44857562.99
pmol/l
0.19
43
350
101
842
1.36
1.46
3.5
2.7
147.72
138.18
ug/l
0.17
94
779
10
46
2.23
1.42
1.2
1.1
—
—
—
0
0
10
46
2.23
1.42
2.8
1.5
—
—
—
0
0
10
46
2.23
1.42
1.2
1.1
—
—
—
0
0
46
337
1.46
1.41
2.6
2.9
0.78
0.94
e6/l
0.27
31
190
115
983
1.34
1.39
5.8
3.8
0.17
0.02
estimate
0.40
18
190
113
964
1.34
1.38
5.8
3.7
0.00
0.00
estimate
-0.00
19
200
23
144
1.66
1.38
8.3
8.8
24.46
24.08
mmol/l
0.11
23
137
10
48
2.13
1.29
3.3
2.8
0.00
2.59
index
—
5
29
9
44
2.09
1.28
1.1
1.3
—
—
—
0
0
154
1385
1.34
1.27
4.2
3.8
15.18
14.97
pmol/l
0.41
143
1237
189
1756
1.43
1.26
6.5
6.6
39.22
39.79
mmol/mol
0.35
175
1628
11
56
2.01
1.24
2.0
3.4
1.08
3.32
ratio
—
6
31
51
390
1.40
1.24
4.4
3.8
4133.60
515.60
ng/l
0.55
42
333
8
37
2.20
1.22
2.0
3.5
8.36
9.68
pmol/l
—
8
37
68
556
1.32
1.08
3.2
3.1
0.19
0.54
e6/l
2.43
52
411
15
90
1.71
1.07
7.5
10.3
1.68
1.65
%
0.06
15
82
19
122
1.61
1.06
1.5
1.8
—
—
—
0
0
9
46
1.99
1.05
1.1
1.4
—
—
—
0
0
7
35
2.03
1.01
1.0
1.5
—
—
—
0
0
57
459
1.32
1.00
2.3
2.5
—
—
—
0
0
0
31
0.00
0.97
0.0
1.8
—
—
—
0
0
87
745
1.27
0.96
5.9
3.7
0.06
0.02
estimate
0.23
18
172
9
51
1.80
0.95
1.1
1.4
—
—
—
0
0
12
70
1.75
0.94
1.0
1.1
—
—
—
0
0
10
55
1.86
0.93
1.5
1.3
—
—
—
0
0
11
63
1.78
0.92
1.2
1.3
—
—
—
0
0
8
42
1.94
0.89
1.0
1.5
—
—
—
0
0
44
351
1.31
0.83
2.3
1.9
—
—
—
0
0
18
124
1.49
0.78
12.5
14.0
15.86
15.75
%
0.06
18
118
11
67
1.67
0.76
2.5
2.3
—
—
—
0
0
29
221
1.36
0.74
9.8
7.4
—
—
—
0
0
31
239
1.34
0.74
5.7
4.8
31.29
31.07
%
0.03
24
151
17
117
1.49
0.74
1.7
1.7
—
—
—
0
0
7
39
1.82
0.73
1.4
1.9
—
—
—
0
0
5
25
2.02
0.73
3.6
2.9
106.40
106.28
mmol/l
—
5
25
5
25
2.02
0.73
3.6
2.9
1.23
1.18
mmol/l
—
5
25
38
303
1.30
0.73
9.9
6.3
102.68
104.42
mmol/l
1.69
38
303
18
126
1.46
0.73
1.8
1.8
—
—
—
0
0
34
269
1.31
0.69
2.0
1.9
—
—
—
0
0
5
27
1.87
0.69
2.6
3.1
—
—
—
0
0
7
43
1.65
0.67
1.0
1.3
—
—
—
0
0
81
713
1.21
0.67
4.2
3.2
—
—
—
0
0
32
254
1.30
0.64
2.0
1.9
—
—
—
0
0
63
546
1.21
0.60
6.2
4.0
0.00
0.01
estimate
0.50
15
180
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
26
204
1.31
0.57
3.6
3.4
3.18
1.60
mmol/l
1.37
21
174
9
62
1.47
0.53
1.3
1.7
—
—
—
0
0
109
1002
1.17
0.53
2.6
2.8
—
—
—
0
0
188
1807
1.22
0.52
5.3
5.2
5.94
6.04
mmol/l
0.62
176
1644
9
64
1.42
0.52
1.8
1.7
—
—
—
0
0
16
118
1.38
0.51
14.9
7.8
25.38
25.13
mmol/l
0.14
16
118
40
467
0.83
0.48
2.5
3.1
0.74
0.82
ug/l
0.25
24
303
21
165
1.30
0.47
1.9
2.0
355.14
414.61
nmol/l
1.18
21
156
7
50
1.41
0.45
1.3
1.3
—
—
—
0
0
56
631
0.85
0.45
4.0
4.8
20.72
21.31
%
0.10
25
305
18
140
1.31
0.43
14.7
9.4
94.64
93.59
%
0.67
18
140
5
31
1.63
0.43
1.6
1.5
—
—
—
0
0
16
123
1.32
0.41
2.9
3.3
25.68
24.01
mmol/l
1.08
16
123
0
15
0.00
0.41
0.0
1.1
—
2.88
—
0
15
0
17
0.00
0.41
0.0
1.8
—
—
—
0
0
8
60
1.35
0.40
1.3
1.6
—
—
—
0
0
176
1697
1.16
0.39
5.6
4.7
2.00
1.97
mu/l
0.15
165
1527
9
71
1.28
0.36
2.3
1.8
—
—
—
0
0
10
73
1.39
0.35
1.4
1.6
—
—
—
0
0
6
47
1.28
0.32
1.2
1.3
16.93
30.04
u/l
—
6
39
28
241
1.18
0.31
1.7
1.5
—
—
—
0
0
8
62
1.30
0.28
1.1
1.3
—
—
—
0
0
8
62
1.30
0.28
1.4
1.5
—
—
—
0
0
199
1953
1.14
0.24
29.6
21.5
75.66
79.64
umol/l
1.23
199
1929
198
1943
1.14
0.23
14.7
11.7
26.84
26.28
u/l
0.13
193
1875
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
28.60
—
0
5
0
10
0.00
0.21
0.0
5.1
—
225.80
—
0
10
126
1215
1.08
0.21
4.2
3.2
62.84
51.72
u/l
0.27
120
1138
18
155
1.17
0.20
1.7
1.5
—
—
—
0
0
6
53
1.14
0.19
1.3
1.4
—
—
—
0
0
80
761
1.08
0.18
1.8
2.0
1.44
1.34
mmol/l
0.50
70
625
14
120
1.18
0.16
3.4
2.6
0.59
0.65
%
0.41
14
120
34
316
1.09
0.13
2.5
3.0
2.37
2.27
e6/l
0.03
19
169
14
123
1.15
0.13
3.4
2.6
1.31
1.09
%
0.81
14
123
24
222
1.09
0.10
1.7
1.6
—
—
—
0
0
5
48
1.04
0.09
1.0
1.5
—
—
—
0
0
77
792
0.96
0.08
4.7
5.5
2.23
2.28
ug/l
0.05
64
713
20
215
0.92
0.08
5.2
3.6
—
—
—
0
0
70
687
1.03
0.04
3.5
4.0
9.39
10.08
mg/mmol
0.05
46
447
174
1751
0.97
0.03
4.8
4.3
1.29
1.26
mmol/l
0.16
159
1589
53
537
0.98
0.01
4.8
3.2
0.00
0.01
estimate
0.50
17
154
187
1869
1.00
0.00
5.9
5.9
2.73
2.61
mmol/l
1.08
174
1709
183
1831
1.00
0.00
5.3
5.0
1.49
1.44
mmol/l
0.70
171
1668
184
1837
1.01
0.00
5.5
5.1
4.67
4.50
mmol/l
1.51
173
1692
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
4.47
—
0
6
0
6
0.00
-0.00
0.0
4.2
—
10.12
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
-0.00
0.0
3.3
—
129.57
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
-0.00
0.0
1.2
—
87.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
1.53
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
9.44
—
0
9
Mortality – FinRegistry
↥Association
Association between endpoint M13_MUSCLEATROPH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MUSCLEATROPH | 2.0 [1.43, 2.8] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.168 |
During the follow-up period (1.1.1998 — 31.12.2019), 100 out of 431 females with M13_MUSCLEATROPH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MUSCLEATROPH | 2.175 [1.62, 2.92] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.012 |
During the follow-up period (1.1.1998 — 31.12.2019), 165 out of 582 males with M13_MUSCLEATROPH died.
Mortality risk
Mortality risk for people of age
years, who have M13_MUSCLEATROPH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.222% | 0.409% |
| 5 | 1.237% | 2.655% |
| 10 | 3.025% | 6.217% |
| 15 | 5.429% | 11.554% |
| 20 | 9.286% | 19.826% |
Relationships between endpoints
↥Index endpoint: M13_MUSCLEATROPH – Muscle wasting and atrophy, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data